186 related articles for article (PubMed ID: 21148330)
1. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.
Gerbaulet A; Wickenhauser C; Scholten J; Peschke K; Drube S; Horny HP; Kamradt T; Naumann R; Müller W; Krieg T; Waskow C; Hartmann K; Roers A
Blood; 2011 Feb; 117(6):2012-21. PubMed ID: 21148330
[TBL] [Abstract][Full Text] [Related]
2. Constitutive Kit activity triggers B-cell acute lymphoblastic leukemia-like disease in mice.
Weidemann RR; Behrendt R; Schoedel KB; Müller W; Roers A; Gerbaulet A
Exp Hematol; 2017 Jan; 45():45-55.e6. PubMed ID: 27664314
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
[TBL] [Abstract][Full Text] [Related]
4. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.
Soucie E; Hanssens K; Mercher T; Georgin-Lavialle S; Damaj G; Livideanu C; Chandesris MO; Acin Y; Létard S; de Sepulveda P; Hermine O; Bernard OA; Dubreuil P
Blood; 2012 Dec; 120(24):4846-9. PubMed ID: 23074272
[TBL] [Abstract][Full Text] [Related]
5. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase.
Kitayama H; Tsujimura T; Matsumura I; Oritani K; Ikeda H; Ishikawa J; Okabe M; Suzuki M; Yamamura K; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1996 Aug; 88(3):995-1004. PubMed ID: 8704259
[TBL] [Abstract][Full Text] [Related]
6. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
7. c-Kit and c-kit mutations in mastocytosis and other hematological diseases.
Boissan M; Feger F; Guillosson JJ; Arock M
J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573
[TBL] [Abstract][Full Text] [Related]
8. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
11. Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
Palam LR; Mali RS; Ramdas B; Srivatsan SN; Visconte V; Tiu RV; Vanhaesebroeck B; Roers A; Gerbaulet A; Xu M; Janga SC; Takemoto CM; Paczesny S; Kapur R
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467326
[TBL] [Abstract][Full Text] [Related]
12. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.
Yavuz AS; Lipsky PE; Yavuz S; Metcalfe DD; Akin C
Blood; 2002 Jul; 100(2):661-5. PubMed ID: 12091362
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
15. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
Yang Y; Létard S; Borge L; Chaix A; Hanssens K; Lopez S; Vita M; Finetti P; Birnbaum D; Bertucci F; Gomez S; de Sepulveda P; Dubreuil P
Blood; 2010 Aug; 116(7):1114-23. PubMed ID: 20484085
[TBL] [Abstract][Full Text] [Related]
16. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G; Metcalfe DD; Olivera A
Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
[TBL] [Abstract][Full Text] [Related]
17. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
18. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
[TBL] [Abstract][Full Text] [Related]
19. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
20. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
Piao X; Bernstein A
Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
